000 01159 a2200325 4500
005 20250513043641.0
264 0 _c19950727
008 199507s 0 0 eng d
022 _a0025-7125
024 7 _a10.1016/s0025-7125(16)30045-1
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aTschida, S J
245 0 0 _aAnti-infective agents and hepatic disease.
_h[electronic resource]
260 _bThe Medical clinics of North America
_cJul 1995
300 _a895-917 p.
_bdigital
500 _aPublication Type: Journal Article; Review
650 0 4 _aAnti-Infective Agents
_xpharmacokinetics
650 0 4 _aChloramphenicol
_xpharmacokinetics
650 0 4 _aClindamycin
_xpharmacokinetics
650 0 4 _aFluoroquinolones
650 0 4 _aHumans
650 0 4 _aIsoniazid
_xpharmacokinetics
650 0 4 _aLiver Diseases
_xdrug therapy
650 0 4 _aMetabolic Clearance Rate
650 0 4 _aRifampin
_xpharmacokinetics
700 1 _aVance-Bryan, K
700 1 _aZaske, D E
773 0 _tThe Medical clinics of North America
_gvol. 79
_gno. 4
_gp. 895-917
856 4 0 _uhttps://doi.org/10.1016/s0025-7125(16)30045-1
_zAvailable from publisher's website
999 _c7790786
_d7790786